Presentation is loading. Please wait.

Presentation is loading. Please wait.

Accessibility to Medicines Under Compulsory Licenses: Anti- HIV/AIDS (Efavirenz, Kaletra) and Clopidogrel Sub-committee for Benefits and Services Development.

Similar presentations


Presentation on theme: "Accessibility to Medicines Under Compulsory Licenses: Anti- HIV/AIDS (Efavirenz, Kaletra) and Clopidogrel Sub-committee for Benefits and Services Development."— Presentation transcript:

1 Accessibility to Medicines Under Compulsory Licenses: Anti- HIV/AIDS (Efavirenz, Kaletra) and Clopidogrel Sub-committee for Benefits and Services Development Meeting on February 14, 2008

2 Stock Management of Anti- HIV/AIDS Medicines EFAVIRENZ 600 mg. Purchasing orders –First batch: 66,000 bottles (stock run out) –Second batch: 100,000 bottles (placed under the VMI system since October 2007) Monitoring on the use of Efavirenz is shown in the Table. LOPINAVIR 133.33 mg RITONAVIR 33.3 mg Kaletra ® is currently prescribed. (571 bottles still in the stock) On January 28, 2008, there were 957 patients (588 adults, 369 children) using this antiviral medicine. 4,000 bottles of Indian generic arrived in stock on February 12, 2008. Monitoring on the use of Lopinavir/Ritonavir is shown in the Table.

3

4

5 Clopidogrel 75 mg. (tab) Already registered by GPO The registered generic drug is produced by Cadila Healthcare, an India company. Purchasing order of the first batch for 2 million tablets has been placed and is currently under the transportation process to Thailand.


Download ppt "Accessibility to Medicines Under Compulsory Licenses: Anti- HIV/AIDS (Efavirenz, Kaletra) and Clopidogrel Sub-committee for Benefits and Services Development."

Similar presentations


Ads by Google